KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash from Investing Activities (2016 - 2026)

Pacira BioSciences has reported Cash from Investing Activities over the past 17 years, most recently at $19.4 million for Q1 2026.

  • For Q1 2026, Cash from Investing Activities rose 175.86% year-over-year to $19.4 million; the TTM value through Mar 2026 reached $144.6 million, up 254.81%, while the annual FY2025 figure was $99.5 million, 219.46% up from the prior year.
  • Cash from Investing Activities for Q1 2026 was $19.4 million at Pacira BioSciences, up from $19.3 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $66.2 million in Q1 2023 and troughed at -$208.0 million in Q1 2022.
  • A 5-year average of -$6.6 million and a median of $7.3 million in 2023 define the central range for Cash from Investing Activities.
  • Biggest five-year swings in Cash from Investing Activities: crashed 1101.36% in 2024 and later skyrocketed 5353.53% in 2025.
  • Year by year, Cash from Investing Activities stood at $11.2 million in 2022, then dropped by 25.16% to $8.4 million in 2023, then crashed by 104.39% to -$368000.0 in 2024, then skyrocketed by 5353.53% to $19.3 million in 2025, then rose by 0.56% to $19.4 million in 2026.
  • Business Quant data shows Cash from Investing Activities for PCRX at $19.4 million in Q1 2026, $19.3 million in Q4 2025, and $43.6 million in Q3 2025.